Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−8.82 USD
−74.75 M USD
107.00 K USD
727.44 K
About Finch Therapeutics Group, Inc.
Sector
Industry
CEO
Matthew P. Blischak
Website
Headquarters
Boston
Founded
2014
FIGI
BBG00ZGYN7N4
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of FNCH is 10.80 USD — it has decreased by −1.82% in the past 24 hours. Watch Finch Therapeutics Group, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Finch Therapeutics Group, Inc. stocks are traded under the ticker FNCH.
FNCH stock has fallen by −7.14% compared to the previous week, the month change is a −5.64% fall, over the last year Finch Therapeutics Group, Inc. has showed a 251.79% increase.
FNCH reached its all-time high on Mar 19, 2021 with the price of 20,290.52 USD, and its all-time low was 0.80 USD and was reached on May 28, 2024. View more price dynamics on FNCH chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
FNCH stock is 8.37% volatile and has beta coefficient of 4.51. Track Finch Therapeutics Group, Inc. stock price on the chart and check out the list of the most volatile stocks — is Finch Therapeutics Group, Inc. there?
Today Finch Therapeutics Group, Inc. has the market capitalization of 17.66 M, it has decreased by −4.84% over the last week.
Yes, you can track Finch Therapeutics Group, Inc. financials in yearly and quarterly reports right on TradingView.
Finch Therapeutics Group, Inc. is going to release the next earnings report on Mar 21, 2025. Keep track of upcoming events with our Earnings Calendar.
FNCH net income for the last quarter is −4.83 M USD, while the quarter before that showed −3.88 M USD of net income which accounts for −24.72% change. Track more Finch Therapeutics Group, Inc. financial stats to get the full picture.
No, FNCH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 24, 2024, the company has 1.00 employees. See our rating of the largest employees — is Finch Therapeutics Group, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Finch Therapeutics Group, Inc. EBITDA is −19.51 M USD, and current EBITDA margin is −30.36 K%. See more stats in Finch Therapeutics Group, Inc. financial statements.
Like other stocks, FNCH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Finch Therapeutics Group, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Finch Therapeutics Group, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Finch Therapeutics Group, Inc. stock shows the sell signal. See more of Finch Therapeutics Group, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.